Clinical Trials Logo

Filter by:
NCT ID: NCT06463548 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine and Lenvatinib for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.

NCT ID: NCT06463522 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1, open label clinical trial of tumor-infiltrating lymphocytes for the treatment of patients with hepatocellular carcinoma. The purpose of this study is to assess the safety of tumor-infiltrating lymphocytes therapy in patients with hepatocellular carcinoma.

NCT ID: NCT06463392 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Deep Learning-based sbORN Diagnostic Model

Start date: June 20, 2024
Phase:
Study type: Observational

Skull-base osteonecrosis (sbORN) is a severe long-term complication of nasopharyngeal carcinoma (NPC) post radiotherapy, which significantly diminish the quality of life, increase the risk of internal carotid artery rupture, and is frequently misdiagnosed as NPC recurrence. Novel diagnostic tools are therefore clinically significant. In this study, the investigators seek to ask if a deep-learning-based model shows a significantly higher sensitivity than radiologists. With a cross-sectional design, the investigators aim to recruit 312 participants in Sun Yat-sen Memorial Hospital, Guangzhou, China that meet the eligibility criteria.

NCT ID: NCT06463171 Not yet recruiting - Clinical trials for Lung Cancer Non-small Cell Stage IV

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Start date: June 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test in Locally Advanced or Metastatic Non-small Cell Lung Cancer patients with EGFR Mutations. The main question it aims to answer is: Evaluation of the Efficacy and Safety of Aumolertinib in Combination with Lastet for the Treatment of EGFR-Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer in First-line Therapy. Participants will be treated with a combination of Aumolertinib and Lastet.

NCT ID: NCT06462417 Not yet recruiting - Allergic Rhinitis Clinical Trials

Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis

Start date: June 20, 2024
Phase: N/A
Study type: Interventional

The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.

NCT ID: NCT06462222 Not yet recruiting - Clinical trials for Leptomeningeal Metastasis

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

Start date: June 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors, to evaluate the safety and efficacy.

NCT ID: NCT06462144 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus (SLE)

IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

Start date: July 1, 2024
Phase: Early Phase 1
Study type: Interventional

This is an exploratory trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of IMPT-514, an autologous, anti-CD19/CD20 CAR T therapy, administered as an intravenous (IV) infusion, in participants with B cell driven autoimmune diseases, including active, refractory Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), and Idiopathic Inflammatory Myopathy (IIM).

NCT ID: NCT06461624 Not yet recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma

Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

A phase I clinical study of 4th generation chimeric antigen receptor T Cells targeting glypican-3 ( CAR-GPC3 T Cells) in patients with advanced hepatocellular carcinoma.

NCT ID: NCT06461338 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Acupuncture for Enhancing Immunotherapy in Advanced NSCLC:a Pilot Study

Start date: June 2024
Phase: N/A
Study type: Interventional

This multicentre, randomized controlled trial evaluates the effect and safety of integrating acupuncture with immunotherapeutic sensitization in treating NSCLC. Participants will be randomly assigned to undergo either acupuncture or sham acupuncture concurrent with the initial four cycles of standard ICIs combined with chemotherapy.

NCT ID: NCT06460831 Not yet recruiting - Atrial Fibrillation Clinical Trials

A Comparative Study Evaluating the Vein of MArshall Ethanol Infusion Ablation Using an Over-the-wire (OTW) Balloon Versus a microcatHeter in Patients With Atrial Fibrillation

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to compare OTW balloon with microcatheter in the Marshall vein alcohol ablation study. The main questions it aims to answer are: • Is there a difference in the effectiveness and safety of OTW balloon and microcatheter in Marshall vein alcohol ablation? Participants will be asked to: Undergo treatment with OTW balloon Undergo treatment with microcatheter If there is a comparison group: Researchers will compare the OTW balloon group and the microcatheter group to see different effects.